摘要：

2018年8月20日，美国FDA网站刊登一则动态，宣布9月10-9月20日对VCRP系统进行维护，这期间系统将不可使用。VCRP(TheVoluntaryCosmeticRegistrati...

2018年8月20日，美国FDA网站刊登一则动态，宣布9月10-9月20日对VCRP 系统进行维护，这期间系统将不可使用。

VCRP (The Voluntary Cosmetic Registration Program )是一个美国市场的报告制度，中译名为化妆品自愿注册计划，适用于在美国销售的制造、包装和分销的化妆品产品。FDA化妆品和色素办公室应化妆品工业的要求制定了化妆品自愿注册计划。计划包括两部分:化妆品生产厂家自愿注册和化妆品成分声明。厂家自愿注册并获得注册号并不表示FDA对该厂家或其产品的批准，FDA也不允许厂家利用参与VCRP或获取的注册号或列名号进行商业宣传。（有没有联系到咱们的国产非特殊用途化妆品备案系统，只是人家包括生产企业和产品，而且是自愿登记，应该就是我们所称的“登记式备案”吧），小编搜集了一些关于该Program的介绍（来自网络，小编不对真实性、准确性担保），学习美帝的化妆品管理经验，在改革的关键时期，希能借他山之石，逐已身之玉。@国家药监局

基本信息

参与的好处

厂家自愿注册并获得注册号并不表示FDA对该厂家或其产品的批准，FDA也不允许厂家利用参与VCRP或获取的注册号或列名号进行商业宣传;但厂家可以通过参与VCRP直接获得下列利益:

获取化妆品成分重要信息。FDA将从VCRP得到的所有信息输入计算机数据库。如果当前使用的某种化妆品成分一旦被认为是有害而应被禁用的，FDA会通过VCRP数据库中的通讯录通知产品的生产商或销售商。如果你的产品不在注册数据库中，FDA将无法通知你。

避免因成分问题导致产品被召回或进口时被扣留。如果化妆品厂家把产品配方在VCRP备案，只要FDA发现厂家在配方中使用了未经批准的色素添加剂或其它禁用成分，就会提醒厂家注意。这样，厂家可以在产品进口或销售前修改产品配方，从而消除了因为不当成分的使用导致产品被召回或扣留的风险。 帮助零售商识别有安全意识的生产商。零售商(例如百货公司)有时询问FDA某家化妆品公司是否在FDA注册过。虽然注册并不表示FDA批准，但它表明你的产品经过了FDA的审阅并且进入了政府的数据库。如果你提交的产品配方不完整，或者包含某种禁用成分或未经批准的色素添加剂，FDA会通知你。

采集样品的决定基于：

产品的性质;

FDA重点关注的问题;

产品的以往历史。

FDA取得一物理样品并将它送到FDA地区实验室进行分析，如果FDA发现样品符合要求，则分别向美国海关和进口商发送一份"放行通知书"。如果FDA断定，样品"有违反FDCA和其它有关法律的表现"，则分别向美国海关和案及进口商发送"扣押和听证通知书"。通知书详细说明违法和性质并给案及进口商10个工作日以提供该批货物可获准许的证据。

已扣押的进口货必须在FDA或美国海关的监督下修整，回输或销毁。

听证会是进口商为进口物品进行辩护或提供证据能够使货物经过修整后适合于入境的唯一机会。

如果案及承销商、货主、进口商或一指定代表不答复通知书，FDA向美国海关和案及进口商发送"拒入通知书"。而后问题所及的产品回输或销毁。

如果案及承销商、货主、进口商或一指定代表答复了"扣押和听证通知书"，当进口商提供证据表明产品"符合要求"或提交修整产品的申请书时，FDA就已扣押的产品举行听证会。

如果商号提供了产品符合要求的证据，FDA将采集后续样品。待分析后决定，产品或是被放行或是被拒绝入境。

FDA审核进口商拟议的修整程序，视情况予以批准或不予批准。一旦批准，FDA将进行后续检验/样品采集以确定其合格性。如果样品合格，向美国海关和进口商发送"放行通知书"。发果样品不合格，出"拒入通知书"。

FDCA的第8(C)节要求申请人支付全部费用，除更新标签或其它使扣押商品符合申请书(FDA-766表格)条款中有关措施的费用外，还包括FDA官员或雇员的差旅、日用和工资。通过提交FDA-766表格，申请人同意按现行法规支付全部监管费用。

认证与检测

FDA监督和规范美国市场上的化妆品，对于出口到美国的化妆品，FDA做入关前抽检。对于抽检不合格的产品，业主可以有一次在FDA前听证上诉的机会，如果FDA证据确凿，则产品退回业主，或就地销毁，销毁或退货的费用由原业主负担。

FDA关心的是产品的安全性，及不良厂家对消费者的误导，FDA有一套完整的认证程序，并且对不同人体部位使用的化妆品有不同规定，已知的有害性物质不可以出现在化妆品成份中，误导的标签在进入美国必须改正。

FDA倡导厂家的自律。如果厂家在FDA的出口记录良好，抽查可以少而且迅速。如果厂家有连续的违规记录，厂家会发现他们以后很难与FDA打交道.

在美国，管理化妆品的法律依据主要是《食品、药品和化妆品法》(FDCA)、《良好包装和标签法》(FPLA)和其它适用法规。

FDCA第801节授权美国食品和药物管理局(FDA)检验通过美国海关进入美国境内的化妆品。检验既可在入境之前，也可在抵达进口商和中间商之后进行。进口商/中间商把向美国海关报关文件副本，连同每次报关物品的发票提交给FDA。美国海关和FDA对报关归档分类以鉴别需FDA执行法律法规的程序。接到报关文件后，对进口产品的初检是记录复核。

通过对化妆品进行记录复核，将做出下列三项之一的决定:

本批放行

本批自动扣押

通过码头检验或取样以进行检验

对于化妆品，码头检验基本上包括对于强制性标签要求的标签检验，以确定化妆品的标签上是否带有或列出下列内容:

配料标签、禁用配料 、英语标签 、不准许使用的色素 、法规要求的警示性说明 、产品需用符合21CFR700.25节要求的抗干扰的包装。

其它强制性标签信息(如制造商工厂的名称和地址，包装商或经销商企业的名称和地址，品名，内容物净含量的公布等)

进行进口检验的检验员可对全部入境产品、多重批次或单一系列产品进行码头检验或抽取样品。取样一般包括对产品的物理采集或文件汇总，用于FDA地区实验室的随后检验。无论何时FDA抽取了样品总会向货主或承销商提供一份取样通知单。检验可包括色素分析，污物分析，微生物分析或化学污染分析。检验也可是复查标签或标签制作，以确定是否符合法规对化妆品的标签制作的要求或是否带有疗效或药物声明。

进口程序如下:

在货物抵达入境口岸之日起的5个工作日内进口商或机构向美国海关总署填报入境文件.

当FDA接到入境通报后，审核进口商的报关单位以确定是否应进行物理检验(码头检验，抽样检验). 如果决定不抽取样品，FDA分别向美国海关和案及进口商发送(可续行通知)。此时，本批货物在FDA处予以放行. 注意"可不经检验续行"并不意味着产品符合要求。它只意味着在产品入境时FDA不予检验。如果日后发现产品违反法律和法规，将视违法的性质启动相应的法律措施(如没收等). 如果决定取样，FDA分别向美国海关和案及进口商发送"取样通知书"该批货物必须保持原样以待进一步通知，FDA将从该批货物中抽取样品。

About VCRP

There are two parts to the VCRP, described in detail in the sections below. You may participate in both parts of the program or only one part. No fees are required to participate in this voluntary program.

The VCRP applies only to cosmetic products being sold to consumers in the United States. It does not apply to cosmetic products for professional use only, such as products used in beauty salons, spas, or skin care clinics. It also does not apply to products that are not for sale (Title 21, Code of Federal Regulations (CFR), part 710.9), such as hotel samples, free gifts, or cosmetic products you make in your home to give to your friends.

Benefits of VCRP Participation

The VCRP assists FDA in carrying out its responsibility to regulate cosmetics. FDA uses the information to evaluate cosmetic products on the market. Because product filings and establishment registrations are not mandatory, voluntary submissions provide FDA with the best information available about cosmetic products and ingredients, their frequency of use, and businesses engaged in their manufacture and distribution (Federal Register, vol. 73, p. 76360, and vol. 69, p. 9339).

 Information from the VCRP database also has been used by the Cosmetic Ingredient Review (CIR), an independent, industry-funded panel of scientific experts, to assist the CIR Expert Panel in assessing ingredient safety and determining priorities for ingredient safety review (Federal Register, vol. 73, p. 76360). FDA representatives attend CIR meetings in a non-voting capacity. By participating in the VCRP you are supporting these safety review processes.

Cosmetic companies gain one additional benefit from VCRP participation. Filers can use the database as back-up storage for product information because the FDA server is secured and off-site.

Some Important Things to Know

There are legal differences between cosmetics and drugs. The VCRP applies to products that are cosmetics as defined by the Federal Food, Drug, and Cosmetic Act (FD&C Act), section 201(i). Drugs are subject to different requirements, including those for registering establishments and listing products with FDA (FD&C Act, sec. 510; 21 CFR 207). Some cosmetic products may also be drugs. Additional information on these types of products is available elsewhere on FDA's website. For example, you may wish to refer to “Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?).” If your products are drugs, or both cosmetics and drugs, see “Drug Registration and Listing System (DRLS & eDRLS)” and “Electronic Drug Registration and Listing Instructions.” 

The VCRP is not a cosmetic approval program or a promotional tool. Cosmetics are not subject to FDA premarket approval. It is the firm's responsibility to ensure that its cosmetic products and ingredients are safe and properly labeled, in full compliance with the law. Registration of a cosmetic establishment, assignment of an establishment registration number, filing a cosmetic product, or assignment of a CPIS number does not mean that FDA has approved the firm or its products (21 CFR 710.8 and 720.9) or that a product is a cosmetic as defined in the FD&C Act. Any representation in labeling or advertising that creates an impression of official approval because of registration or possession of a registration number is considered misleading (21 CFR 710.8 and 720.9). Misleading labeling makes a cosmetic misbranded (FD&C Act, 602(a)), and marketing a misbranded cosmetic is against the law (FD&C Act, 301(a)).

The VCRP is not part of an import notification system. Firms importing products considered to be solely cosmetics in the United States are not required to register with FDA, and a registration number is not required for importing cosmetics into the United States.

Certain information from the VCRP database is available through the Freedom of Information Act (FOIA). For example, FDA sometimes receives such requests from consumers or healthcare providers who wish to identify products that do or do not contain certain ingredients. Proprietary business information, however, is not releasable under FOIA. Firms may submit written requests for confidentiality of a cosmetic ingredient in accordance with 21 CFR 720.8, which also states how FDA handles such requests.

The regulations authorizing this program are found in 21 CFR, parts 710 and 720.

How to Participate

1) Registering cosmetic manufacturing and/or packaging establishments. Cosmetic establishments are facilities where cosmetics are manufactured and/or packaged, not locations that house only business operations. Only owners or operators of cosmetic manufacturing or packing facilities can register their establishments, using a separate Form FDA 2511 for each facility location. Distributors cannot register an establishment (21 CFR 710.1). Firms can register their establishments before or after their products are entered into commercial distribution and for sale to U.S. consumers. FDA assigns a registration number to each establishment location.

2) Filing Cosmetic Product Ingredient Statements (CPIS). A cosmetic manufacturer, packer, or distributor can file a statement for each product the firm has entered into commercial distribution in the United States. Use a separate Form FDA 2512 for each formulation. (If you are using printed forms, you will need both Form FDA 2512 and 2512a.) You also may file a CPIS to amend an earlier submission if you change the formulation. FDA assigns a Cosmetic Product Ingredient Statement Number (CPIS NO.) to each formulation filed in the VCRP.

3) Amending or Discontinuing a Product Formulation. CPIS numbers do not have expiration dates, so it is important for you to follow the procedures in 21 CFR 720.6 to amend a filed formulation or to discontinue a filed product that is no longer in commercial distribution. Use Form FDA 2512 to amend or discontinue a CPIS. 

来源：浙里辨妆，原创铭江。